TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Dr. Michel Janicot as consultant Senior Development Officer, a move that adds more than 35 years of global oncology drug-development experience to the company. Dr. Janicot will support the advancement of TransCode's lead therapeutic candidate, TTX-MC138, and its other investigational programs, including Seviprotimut-L.
Dr. Janicot is the founder of JMi ONConsulting and previously held senior leadership positions at Rhône-Poulenc Rorer and Janssen. His expertise spans RNA biology, preclinical strategy, translational medicine, and early clinical development. In his new role, he will guide TransCode's strategic R&D initiatives as the company progresses its investigational oncology programs toward later-stage clinical trials.
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. Additionally, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome RNA delivery challenges and unlock therapeutic access to novel genetic targets relevant to various cancers.
The appointment of Dr. Janicot comes at a critical time as TransCode seeks to advance its pipeline. With his extensive background, the company expects to accelerate development timelines and enhance the strategic direction of its programs. For more details on the announcement, visit https://ibn.fm/TAIIy.
Investors can stay updated on the latest news and developments from TransCode at the company's newsroom: https://ibn.fm/RNAZ.
